Treatment of Depression With Methylphenidate in Patients Difficult to Wean From Mechanical Ventilation in the Intensive Care Unit
J Clin Psychiatry 2000;61:750-755
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Mechanical ventilation is often
required to support patients in the intensive care unit (ICU)
with life-threatening cardiovascular, respiratory, or
neuromuscular disorders. Occasionally, difficulties related to
weaning patients from this support occur owing to depression. The
traditional and newer-generation antidepressant drugs have a
relatively long latency of response that interferes with
rehabilitation attempts in the ICU. Psychostimulants such as
methylphenidate show a rapid onset of antidepressant activity and
a benign side effect profile.
Method: As consulting psychiatrists in the
consultation-liaison service of a university hospital, we treated
7 patients with complex ICU courses presenting prolonged
mechanical ventilation and psychomotor retardation associated
with markedly depressed mood (DSM-IV criteria) by giving them
methylphenidate. Methylphenidate was started on the first day at
a dose of 2.5 mg p.o. in the morning and was increased by 2.5 mg
each day with twice-a-day dosing in the morning and at noon until
the patient responded or showed side effects. A maximum dose of
15 mg/day was not exceeded. Outcome evaluation was performed
using the Clinical Global Impressions scale.
Results: Five (71%) of 7 patients showed marked
or moderate improvement in mood and activity within 3 to 4 days,
and discontinuation of ventilator support was achieved within 8
to 14 days. Side effects with these 5 patients were not
encountered. Of the remaining 2 patients (29%), 1 developed
psychomotor agitation and anxiety within 4 days. Another patient
showed only minimal improvement with regard to activity.
Conclusion: Methylphenidate might be a rapidly
effective and safe treatment for depression in difficult-to-wean
patients hospitalized for life-threatening medical illness in the
ICU. Implications for future research for this population of
patients warrant formal randomized, prospective, clinical